{"id":"W4281629140","doi":"10.1200/jco.2022.40.16_suppl.tps7588","title":"CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Rituximab; Follicular lymphoma; Internal medicine; Refractory (planetary science); Phases of clinical research; Oncology; Neutropenia; Gastroenterology; Lymphoma; Chemotherapy; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001242451,0.0009244882,0.001518802,0.0003749434,0.0003540131,0.001427505,0.0008511353,0.001189222,0.003868173],"category_scores_gemma":[0.00116153,0.0004734545,0.00132608,0.0003987757,0.0007054295,0.0006746414,0.0004090179,0.00280952,0.000944683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001012427,"about_ca_system_score_gemma":0.001190623,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001341459,"about_ca_topic_score_gemma":0.003991643,"domain_scores_codex":[0.9997321,0.000127025,0.00001376831,0.00004279567,0.00003009109,0.00005420405],"domain_scores_gemma":[0.9995485,0.00008073195,0.0001016948,0.00003360133,0.00002590368,0.0002096527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8895015,0.01545889,0.004176512,0.001195911,0.001867535,0.0002609759,0.0002267668,0.001076728,0.01599938,0.0004008981,0.003919328,0.06591558],"study_design_scores_gemma":[0.8683167,0.1197459,0.005714658,0.00007031117,0.0007166092,0.0002966135,0.00005766786,0.0009515547,0.001058733,0.0002663173,0.002786317,0.00001870222],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851575,0.006103098,0.0004281194,0.001154869,0.0003073502,0.001881895,0.001345477,0.0001510907,0.003470647],"genre_scores_gemma":[0.987478,0.003068773,0.000971118,0.001199712,0.0002041718,0.001726215,0.002414472,0.00002885662,0.002908717],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003868173,"threshold_uncertainty_score":0.01294029,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1309022320469332,"score_gpt":0.4447035934095154,"score_spread":0.3138013613625821,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}